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ABSTRACT  
   
Alzheimer's Disease (AD) is the sixth leading cause of death in the United States 
and the most common form of dementia. Its cause remains unknown, but it is known to 
involve two hallmark pathologies: Amyloid Beta plaques and neurofibrillary tangles 
(NFTs). Several proteins have been implicated in the formation of neurofibrillary tangles, 
including Tau and S100B. S100B is a dimeric protein that is typically found bound to 
Ca(II) or Zn(II). These experiments relate to the involvement of S100B in Alzheimer's 
Disease-related processes and the results suggest that future research of S100B is 
warranted. Zn(II)-S100B was found to increase the rate at which tau assembled into 
paired helical filaments, as well as affect the rate at which tubulin polymerized into 
microtubules and the morphology of SH-SY5Y neuroblastoma cells after 72 hours of 
incubation. Zn(II)-S100B also increased the firing rate of hippocampal neurons after 36 
hours of incubation. Together, these results suggest several possibilities: Zn(II)-S100B 
may be a key part of the formation of paired helical filaments (PHFs) that subsequently 
form NFTs. Zn(II)-S100B may also be competing with tau to bind tubulin, which could 
lead to an instability of microtubules and subsequent cell death. This finding aligns with 
the neurodegeneration that is commonly seen in AD and which could be a result of this 
microtubule instability. Ultimately, these results suggest that S100B is likely involved in 
several AD-related processes, and if the goal is to find an efficient and effective 
therapeutic target for AD, the relationship between S100B, particularly Zn(II)-S100B, 
and tau needs to be further studied.  
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Chapter 1 
INTRODUCTION 
Alzheimer’s Disease (AD) is the sixth leading cause of death in the United States 
and the only cause of death among the top ten that cannot be prevented, treated, or cured. 
It is the most common form of dementia; there were 26.6 million sufferers worldwide in 
2006, and it is predicted to affect 1 in 85 people globally by 2050 (Brookmeyer, Johnson, 
Ziegler-Graham, & Arrighi, 2007).  The most commonly recognized symptom is 
forgetfulness, or the inability to acquire new memories; other symptoms include 
confusion, mood swings, aggression and irritability and long-term memory loss 
(Waldemar et al., 2007).  There is no cure for AD, and although the goal of treatment is 
to slow the progression of the disease, this has proven very difficult.  
Generally, AD affects the cerebral cortex, specifically in the parietal and temporal 
lobes, and the hippocampus, which is located in the medial temporal lobe. (Wenk, 2003). 
The cerebral cortex as a whole plays a key role in memory, attention, perceptual 
awareness, thought, and language (Shipp, 2007).  The parietal and temporal lobes are 
association areas, which function to produce a perceptual experience of the world, enable 
people to interact with one another, and support abstract thinking and language. The 
parietal lobe integrates sensory information from different modalities and helps determine 
spatial sense and navigation (Fogassi & Luppino, 2005). The temporal lobe is involved in 
auditory perception as well as processing semantics in both speech and vision. It also 
contains the hippocampus and plays a key role in the formation of long-term memory 
(Squire, Stark, & Clark, 2004).  
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 Neurons are electrically excitable cells that process and transmit information by 
electrical and chemical signaling and they require specialized connections, called 
synapses, with other neurons that they use for communication. Neurons normally connect 
to one another to form neural networks; this is how signals are received from the brain 
and spinal cord and transmitted to glands, muscles, and other parts of the body. There is a 
wide variety in shape, size, and electrochemical properties of neurons, but all share the 
same basic structure (Figure 1). The cell body is the central part of the neuron, and it 
contains the nucleus of the cell. The dendrites of a neuron are cellular extensions that 
may have many branches; this is where the majority of input to the neuron occurs. The 
axon is the finer, cable-like projection that extends much further than the dendrites that 
carries nerve signals away from the cell body. Most neurons have only one axon, but it 
can become branched in order to enable communication with many target cells. The 
terminal end of the axon contains synapses, which are specialized structures where 
neurotransmitters are released to communicate with target neurons. The interconnection 
of neurons with one another is what forms the pathways for signals to be carried all over 
the body. When these networks or pathways are interrupted, the electrical or chemical 
signal carrying the message gets stopped and can’t reach its final destination, resulting in 
a breakdown between the signal the brain receives and the response it intended to trigger. 
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Figure 1. Structure of a typical neuron. (Pearson Education) 
The second cell type involved in AD is astrocytes, which are known to perform 
many functions, including biochemical support of the endothelial cells that form the 
blood-brain barrier (BBB), provision of nutrients to the nervous tissue, maintenance of 
extracellular ion balance, and a role in the repair and scarring process of the brain and 
spinal cord after traumatic injuries (Felts & Smith, 1996).  Astrocytes are star-shaped 
glial cells that exist primarily in the brain and spinal cord, and they are the most abundant 
cell in the human brain. They are closely associated with neurons, and have many 
processes that envelope neuronal synapses.  In this way, they help regulate the 
transmission of electrical impulses within the brain.  
Learning and memory are induced by a process termed synaptic plasticity, which 
is the modulation of the strength of synaptic connections between neurons in the brain 
(Owen & Brenner, 2012). This modulation can be a response to either use or disuse of 
transmission over the synaptic pathways or from the alteration of the number of receptors 
located on a synapse. The underlying mechanisms that contribute to synaptic plasticity 
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include changes in the quantity of neurotransmitters released into a synapse and changes 
in how effectively cells respond to the neurotransmitters. (Gaiarsa, Caillard, & Ben-Ari, 
2002).  
The cause and progression of AD are not completely understood, but the 
pathology of the disease is associated with two major findings: amyloid beta (Aβ) 
plaques and neurofibrillary tangles (NFTs) in the brain (Tiraboschi, Hansen, Thal, & 
Corey-Bloom, 2004).  Aβ plaques are extracellular deposits of amyloid in the gray matter 
of the brain, and are associated with degenerative neural structures and an abundance of 
microglia and astrocytes. Neurofibrillary tangles (NFTs), on the other hand, are formed 
from a hyperphosphorylated form of a microtubule-associated protein (MAP), known as 
tau.  NFT formation produces insoluble aggregations of tau that interfere with normal 
neuronal pathways in the brain (Figure 2, (Mandelkow, 1999)).  
 
Figure 2. Hyperphosphorylation and aggregation of tau. (Mandelkow, 1999) 
  
Tau is a neuronal MAP found mainly in axons and its main function is to 
stimulate and stabilize microtubule assembly from tubulin subunits (L. X. Zhou et al., 
2007), though it also functions in signal transduction, interaction with the actin 
cytoskeleton, neurite outgrowth, interactions with the plasma membrane, and the 
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anchoring of enzymes such as protein kinases and phosphatases (Vladmimir N. Uversky, 
1998). Tau is primarily active in the distal portions of axons, and is present in dendrites to 
a lower degree. Microtubules are a main cytoskeletal element in eukaryotic cells and are 
particularly abundant in nerve cells. Generally, the structure of microtubules is very 
dynamic and thus requires the stabilization provided by MAPs like tau (Vladmimir N. 
Uversky, 1998). Though somewhat regulated by phosphorylation, hyperphosphorylation 
of tau proteins can result in MAP dissociation from microtubule, which destabilizes them 
and leads to tau aggregation into NFTs and paired helical filaments (PHFs).  PHFs are 
aggregations of hyperphosphorylated tau protein that are the components of NFTs. 
Phosphorylated tau has a “nearly maximal extension and is comparatively stiff” 
(Hagestedt, Lichtenberg, Wille, Mandelkow, & Mandelkow, 1989), where un-
phosphorylated tau is highly elastic. Tau is typically highly soluble and survives heat, 
denaturing agents, and acid treatment without loss of its biological function because it is 
virtually void of secondary structure (Hagestedt et al., 1989).   
In terms of affecting the stability of microtubules, tau can do this via isoforms 
and/or phosphorylation. The composition of tau is predominantly hydrophilic and 
charged amino acid residues, and the C-terminal half of tau is what constitutes the 
microtubule-binding domain (Noble, Pooler, & Hanger, 2011). There are six tau isoforms 
that exist in brain tissue, three having three binding domains and three having four 
binding domains. These are a result of alternative splicing of the tau gene. 
Phosphorylation of tau is regulated by kinases, including protein kinase N (PKN), and 
when PKN is activated, it phosphorylates tau, which results in a disruption of the 
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microtubule organization. Because this increases the pool of insoluble tau, this could be 
an important first step in generating available protein for the formation of PHFs.  
 The mechanism by which tau is converted from its water-soluble form into 
pathogenic insoluble fibrils is not clearly understood, but recently there is increasing 
evidence to suggest the involvement of zinc. It is well established that the homeostasis of 
transition metals is altered significantly in AD, with extracellular pooling of zinc and 
copper in amyloid, and intraneuronal accumulation of iron (Bush, 2012). It has also been 
shown that zinc released into the brain is needed to maintain memory and cognition 
(Adlard, Parncutt, Finkelstein, & Bush, 2010). Furthermore, it has been reported that zinc 
accelerates in vitro tau fibrillization, though the mechanism for this is unknown (F. Zhou, 
Chen, Xiong, Li, & Qu, 2012). In the brain, zinc is released into the synaptic cleft and 
routinely reaches concentrations of 10-20 µM. It also seems to accumulate in and around 
NFTs, which are characterized by hyperphosphorylated tau protein, and correlates with 
the severity of dementia in tauopathies like AD (Religa et al., 2006). It has recently been 
shown that zinc can accelerate the aggregation of a tau peptide, which is the major 
protein subunit of a NFT, but it is not known whether or not zinc can trigger the 
hyperphosphorylation of tau (Mo et al., 2009).  
 Another protein that has been implicated as a major player in AD and other 
neurological conditions is S100 calcium binding protein B, or S100B. S100B is a 
member of the S100 family of proteins, which are proteins that are soluble in nearly 
saturating (100%) ammonium sulfate and that contain 2 EF-hand motifs that display 
varying affinities for calcium (Cox, 1998).  The EF-hand motif contains a helix-loop-
helix topology in which the calcium ions are coordinated by ligands within the loop. Both 
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EF-hands are flanked by hydrophobic regions at the C and N terminals and are separated 
by a centrally located hinge region. Generally, S100 proteins are located in the cytoplasm 
and/or the nucleus of a wide variety of cells, and are involved in the regulation of various 
cellular processes, including interactions with tubulin and glial fibrillary acidic protein 
(Smith & Shaw, 1998). S100B is a glial-specific protein that is primarily expressed by 
astrocytes.  
 One of S100B’s main functions is to enhance the neurite extension of cortical 
neurons and to stimulate proliferation of glial cells. On the other hand, it also plays a role 
in the inhibition of protein kinase C (PKC)-mediated phosphorylation, astrocytosis and 
axonal proliferation, and inhibition of microtubule assembly (Zimmer, Cornwall, Landar, 
& Song, 1995). It is in the developing central nervous system (CNS) that S100B acts as a 
neurotrophic factor and induces the survival, development, and function of neurons 
(Reichardt, 2006). S100B’s other functions, including astrocytosis, axonal proliferation, 
and inhibition of microtubule assembly are thought to occur when S100B is present 
extracellularly (Zimmer et al., 1995). This diversity of function is accomplished by the 
ability of S100B to adopt a variety of conformations based on the presence of divalent 
metal cations, e.g., Ca(II), Zn(II) and Cu(II) (Aimee Landar, 1997).  Some activities, such 
as the enhancement of neurite extension and the proliferation of glial cells, are ascribed to 
S100B's disulfide-linked dimeric form, in which two monomers, each “formed by two 
helix-loop-helix EF-hand calcium binding motifs joined by a flexible linker region” are 
joined (Smith & Shaw, 1998).  
In a developing central nervous system, S100B acts as a neurotropic factor as well 
as a neuronal survival protein. In adults, it is typically elevated in nervous system 
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damage, making it a potential clinical marker for various conditions, including stroke, 
concussive brain injury and dementia-related diseases such as AD and Parkinson’s 
(Michetti et al., 2012). Subsequently, S100B has been implicated in AD and other 
neurological conditions, based on increased levels of the protein in affected brains 
compared to unaffected brains as well as the fact that the brains of AD patients display 
evidence of increased oxidative stress, which has been suggested to be related to 
unregulated redox-active metals in the brain such as copper, iron, and zinc (Hung, Bush, 
& Cherny, 2010). Although S100B is a calcium-binding protein, it is also known to bind 
zinc. However, there are currently no indications as to how the S100B dimer is formed in 
vivo.  
 The tubulin family of proteins, including alpha-tubulin and beta-tubulin, are 
building blocks for the formation of microtubules. The polymerization of tubulin occurs 
when dimers of alpha-tubulin and beta-tubulin bind to Guanosine-5’-triphosphate (GTP) 
and assemble onto the positive ends of microtubules while in the GTP-bound state (Heald 
& Nogales, 2002). After the dimer becomes incorporated into the existing microtubule, 
the GTP that remains bound to the beta-tubulin subunit eventually hydrolyzes into 
Guanosine-5’diphosphate (GDP); the stability of the dimer is affected by whether the 
beta-tubulin is bound to GTP or GDP. Dimers that are bound to GTP are more readily 
able to assemble into microtubules, while dimers that are GDP-bound are more likely to 
fall apart. This cycle is critical to the inherent dynamic instability of microtubules that 
renders them able to quickly switch between growing and shrinking phases (Howard & 
Hyman, 2003). It has been shown in vitro that S100B modulates this assembly and 
disassembly of microtubules. In the presence of Ca(II), S100B caused a rapid and nearly 
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complete disassembly of preformed microtubules in a calcium and pH-dependent manner 
(Sorci, Agneletti, Bianchi, & Donato, 1998).   
 Tubulin has also been identified as one of several “best potential targets” for 
S100B via a consensus sequence. More than 20 proteins that were found to interact in 
vitro with S100B in a calcium-sensitive manner were screened for the sequence, and 
those proteins showing a high-match frequency across species were further examined. 
Tubulin was one of 8 proteins that showed a 100% match. The sequence match indicates 
an S100B interaction with tubulin domains that would inhibit the polymerization of 
tubulin (McClintock & Shaw, 2000). It has also been shown that S100 protein (a mixture 
of S100A and S100B) “exhibits a significant inhibition on tubulin-dependent Ca(II)-
ATPase activity of microtubule-associated proteins (MAPs). The ATPase activity in the 
absence of tubulin, however, was not affected by the S100 protein” (Asai, Miyasaka, 
Kondo, & Fuju, 1988).  
 Tau has also been shown to affect tubulin polymerization. In normal cells, tau 
stabilizes microtubules. In AD, however, tau does not interact properly with 
microtubules, so they begin to dissociate. Therefore, the tau-microtubule interaction may 
be an important step on the way to understanding the pathology of AD. It has been shown 
in several studies that the hyperphosphorylation of tau decreases its affinity for 
microtubules, which leads to a lack of tau providing the support needed for efficient 
microtubule assembly. Phosphorylation is the most commonly described post-
translational modification of tau, and abnormal phosphorylation occurs before the onset 
of NFTs (Martin, Latypova, & Terro, 2011). There are at least 85 possible 
phosphorylation sites on tau and various kinases and phosphatases that regulate the 
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phosphorylation (Martin et al., 2011). The majority of these phosphorylation sites are 
serines or threonines, and only a small number are tyrosines. Phosphorylation at all sites 
has not been studied, but phosphorylation at certain sites has been shown to decrease tau 
binding to microtubules significantly (Sengupta et al., 1998) and (Dickey et al., 2007).  
 Furthermore, it has been suggested that tau adopts a state that is reminiscent of 
PHFs when it is adsorbed the microtubule surface. While the structure of this state 
remains unknown, one possibility is that the structure resembles “that of a tau oligomer in 
a state of aggregation that resembles a PHF nucleus” (Ackmann, Wiech, & Mandelkow, 
2000). This would coincide with “the number of tau molecules that are sufficient for PHF 
nucleation in the presence of polyanions” (Friedhoff, von Bergen, Mandelkow, Davies, & 
Mandelkow, 1998). Thus, while yet unproven, it remains possible that, in vivo, PHF 
elongation could take place directly on the microtubule surface. Furthermore, the nucleus 
of this PHF assembly is likely to have a specific structure, which represents yet another 
possible therapeutic target.  
After PHFs have formed, they eventually aggregate into NFTs (figure 7). In non-
pathological conditions, tau has been shown to be proteolytically processed by the 
ubiquitin-proteasome-system (UPS), but in pathological conditions, hyperphosphorylated 
tau is rendered “less prone to biochemical degradation” and forms PHFs which are 
subsequently sequestered into NTFs (Martin et al., 2011). Phosphorylation is not the only 
post-translational modification that may affect the formation of PHFs and NTFs, but it is 
certainly the most studied. 
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Figure 3.  Model for multistep process of tau aggregation 
Impairment of tau binding to microtubules results in the increase of monomeric, soluble 
tau that then dimerizes and assembles into oligomers. The oligomers organize in 
protomers, which in turn assemble into PHFs and subsequently NFTs. (Martin et al., 
2011) 
 
Thus, in the last several decades, it has become clear that targeting tau pathology 
for the development of therapeutic drugs for AD is not only promising, but necessary. It 
has already been established that the major biological function of tau is to stimulate 
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microtubule assembly and to stabilize microtubule structure; this biological activity of tau 
is regulated by its degree of phosphorylation. Normally, tau in the human brain contains 
2-3 moles of phosphate per mole of the protein (Iqbal, Liu, Gong, Alonso Adel, & 
Grundke-Iqbal, 2009), and hyperphosphorylation of tau depresses its microtubule 
assembly-promoting activity. It has been seen in the AD affected brain that tau is 
abnormally hyperphosphorylated and is the major building block of PHFs (Binder, 
Guillozet-Bongaarts, Garcia-Sierra, & Berry, 2005). This and other abnormal post-
translational modifications of tau, including “glycosylation, glycation, prolyl-
isomerization, cleavage or truncation, nitration, polyamination, ubiquitination, 
sumoylation, oxidation, and aggregation” (Martin et al., 2011) are what appear to lead to 
the neurofibrillary degeneration in AD.  
The link between NFTs and neurodegeneration has been shown in several animal 
models. In one study done in mouse models, it was shown that mis-folded tau proteins 
induced neurofibrillary degeneration regardless of the difference in the genetic 
background of the mice (Stozicka et al., 2010). In another, transgenic mice expressing 
mutant human tau and non-transgenic mice were used to demonstrate a relationship 
between NFTs and synaptic alterations (Katsuse, Lin, Lewis, Hutton, & Dickson, 2006). 
In AD and other dementia-related diseases, these synaptic alterations have been 
emphasized as an important structural correlate, and several studies have suggested that 
synaptic changes may occur before neuronal loss (DeKosky & Scheff, 1990) and (Terry 
et al., 1991).  Essentially, as tau becomes hyperphosphorylated and aggregates into PHFs, 
which then aggregate into NFTs, it interferes with the normal neuronal pathways in the 
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brain, breaking the line of communication from one neuron to another. This breakdown is 
what leads to the manifested symptoms of AD, such as memory loss and confusion.  
 Studies of the correlation between pathological changes in the brain and cognitive 
impairment have demonstrated that the number of NFTs best correlates with the presence 
or degree of dementia in AD (Iqbal et al., 2009). This provides further evidence that tau 
plays a critical role in neurodegeneration. Further evidence includes a transgenic mouse 
model of amyloid pathology and cognitive deficits where tau was knocked out (Iqbal et 
al., 2009). As a result of the knockout, cognitive deficiencies improved. These, combined 
with other recent findings on tau, make it clear that targeting tau protein for therapeutic 
treatments for AD is promising.  
 Alternative splicing of the tau gene (MAPT) is tissue specific, and there 
are a total of six isoforms of the tau protein found in the central nervous system (CNS). 
The six isoforms contain 352-441 amino acids and have molecular weights ranging from 
37-46 kDa. Tau proteins in the brain can be described according to four domains, an 
acidic projection domain at the amino-terminus, a proline-rich region followed by an 
imperfect microtubule binding repeat motif that is encoded by exons 9-12, and a short 
carboxy-terminal region. Each isoform of tau is characterized by the length of the N-
terminal domain and by the presence of three or four repeat motifs. Diversity of the 
isoforms is further increased by posttranslational mechanisms, including phosphorylation, 
O-glycosylation, ubiquitination, nitration, and glycation. One of the isoforms, the 
shortest, is only expressed in fetal brain, while all six appear in the postnatal period of the 
human brain (Lee, Goedert, & Trojanowski, 2001). There are 79 potential serine and 
threonine phosphate acceptor residues in the longest isoform, and phosphorylation at ~30 
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of these sites has been reported in normal tau proteins (Buee, Bussiere, Buee-Scherrer, 
Delacourte, & Hof, 2000), and tau phosphorylation is developmentally regulated such 
that fetal tau is more highly phosphorylated in embryonic CNS than adult CNS. The tau 
phosphorylation sites are clustered in regions flanking the microtubule binding repeats, 
and it has been established that increasing tau phosphorylation negatively regulates 
microtubule binding (Lee et al., 2001). The different isoforms contain different numbers 
of potential phosphate acceptor residues and can thus be potentially phosphorylated to 
different degrees, which may relate to their susceptibility to form PHFs. 
 
Figure 4.  Differential splicing of the tau gene (Sergeant et al., 2008). (A) The tau gene 
spans more than 130 kb and is composed of 16 exons. (B) Several mRNAs are generated 
by alternative splicing of exons 2, 3, 4A, and 10. (C) In the brain, six major tau isoforms 
are generated via alternative splicing.  
 
Hyperphosphorylation of tau has previously been implicated in PHF formation, 
and there are eighty-five potential phosphorylation sites distributed along a full-length tau 
molecule (Schraen-Maschke et al., 2008).  A high level of phosphorylation on epitopes 
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that are localized at the half N-terminus and C-terminus outside the microtubule binding 
domains predominates as the most common posttranslational modification for tau 
implicated in AD. Normally, the highly basic segments, R3 in 3R tau proteins and R3 and 
R2 in 4R tau proteins, and the C-terminus interfere with polymerization. Upon 
hyperphosphorylation, however, tau proteins adopt the conformation needed to 
polymerize into filaments (Alonso Adel, Mederlyova, Novak, Grundke-Iqbal, & Iqbal, 
2004).  
 Hyperphosphorylation is associated with a loss of microtubule binding capacity 
and a subsequent accumulation in neuronal bodies, and as such is a relatively early event 
in the development of AD. Phosphorylated tau also appears to be more resistant to 
proteolysis by different proteases, which could result in its accumulation in neurons, 
where it contributes to tau toxicity (Schraen-Maschke et al., 2008).  Phosphorylated tau 
(pTau) has thus been suggested as a predictive biomarker of AD. The rationale is that 
pTau is known to be a major component of pre-tangle PHF and mature neurofibrillary 
tangles that are present even before the onset of AD (Schraen-Maschke et al., 2008).  
 So, while it has been established that hyperphosphorylated tau is likely to lead to 
PHF formation, the exact mechanism for how this occurs in vivo has yet to be discovered. 
In normal brain, the amino terminal and carboxy terminal flanking regions to the 
microtubule binding repeats of tau appear to inhibit aggregation into filaments; tau self 
assembles mainly through the microtubule binding domain/repeat R3 in 3R tau proteins 
and through R3 and R2 in 4R tau proteins and hyperphosphorylation of tau neutralizes 
these domains, enabling tau-tau interactions. In AD, however, these regions are 
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phosphorylated and any native inhibition is eliminated, which results in the formation of 
PHFs (Iqbal et al., 2009).  
In vitro, unphosphorylated tau has been shown to polymerize in the presence of 
various polyanions, including heparin and arachidonic acid (ARA), and the subsequent 
structure of PHFs appear to correlate to the structure of AD PHFs when compared via 
electron microscopy (Stefan Barghorn, 2004) and (Shaun W. Carlson, 2007). Based on 
the results of polymerization assays, where varying concentrations of tau protein were 
incubated in the presence of arachidonic acid (ARA) or heparin and polymerization was 
measured via a fluorescent spectrophotometer, these inducer molecules appear to act as 
regulatory molecules or allosteric modifiers of the polymerization reaction (Shaun W. 
Carlson, 2007). It was noted in the same study, that, in the absence of inducer molecules, 
tau exhibits a very high critical concentration for polymerization. Because there was no 
spontaneous nucleation, the polymerization of tau has been hypothesized to be more 
complex than a simple linear polymerization process. The concentration of tau required 
for polymerization was decreased in the presence of the inducer molecules, suggesting 
that the same would be true in vivo, although what the in vivo inducer molecule is, 
remains unknown.  
 In a search for the elusive in vivo inducer of tau polymerization, it has also been 
shown that various molecules other than protein kinases bind to tau under different in 
vivo scenarios. In AD, the acidic protein, S100B, is known to bind tau, likely at the basic 
domain, and potentially cause a change in its ability to be phosphorylated. S100B is a 
small molecular weight zinc-calcium binding protein that is produced by astrocytes (Yu 
& Fraser, 2001). It is upregulated by as much as 20-fold in AD and subsequently has 
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been implicated as a potential target for therapeutic agents if its interaction with tau can 
be better understood. S100B has been shown to directly affect tau in several ways, one of 
which is its ability to block PKC phosphorylation at specific sites (Singh, Wang, et al., 
1996).  The loss of this PKC phosphorylation has been shown to increase the 
susceptibility of tau to hyperphosphorylation (Singh, Zaidi, Grundke-Iqbal, & Iqbal, 
1996), and we know that hyperphosphorylated tau polymerizes into PHFs and 
subsequently the NFTs that are a hallmark pathology of AD.  
 The relationship between S100B and tau is also affected by zinc, which is likely 
attributable to conformational changes of S100B that result in the exposure of a 
hydrophobic domain that could be a key site for tau binding (Yu & Fraser, 2001). 
Assessment of the S100B-tau complex has been done via immunoprecipitation of in vitro 
complexes, and the internalization and subcellular distribution of S100B, in neurons, has 
been studied in neuroblastoma (SH-SY5Y) cells (Yu & Fraser, 2001). The degree of 
S100B internalization by SH-SY5Y cells was affected by zinc; there was more 
internalization when zinc was present than when it was not.  It was also noted that zinc 
produced a much more defined colocalization of S100B with tau when the cells were 
double-labeled with fluorescent tags, suggesting that internalized S100B may be 
associated with tau and thereby affect tau function and/or phosphorylation. For example, 
it has been suggested that S100B may provide a scaffolding for tau to stabilize 
microtubules, which could potentially contribute to the abnormal neuritic dystrophy that 
is observed in AD (Azmitia, Rubinstein, Strafaci, Rios, & Whitaker-Azmitia, 1995), or 
that S100B is a modulator of tau phosphorylation and that any changes in their interaction 
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could be a factor in the AD-related hyperphosphorylation (Sorci, Agneletti, & Donato, 
2000) 
Thus far, several points have been established which further implicate S100B as 
an important player in AD. The first of these is the presence of two cysteine residues in 
S100B that are required for some of its cellular functions. S100B is typically found as a 
dimer, but appears to have two different conformations, one when free from metal, and 
two others when bound to Ca(II) or Zn(II) (Aimee Landar, 1997). The implication of this 
is that the role S100B plays in regulating or affecting tau may be affected by these 
different conformations; subsequently, this may present a location for a future novel 
therapeutic target. Mutation of C68 to a valine did not alter S100B effect on the activity 
of various target proteins, including tau. However, mutation of S100B’s other cysteine 
residue, C84, to serine, resulted in a loss of tau protein modulation (Aimee Landar, 
1997). This suggests that C84 participates in the modulation of tau protein by S100B, but 
not in the modulation of all proteins by S100B.  
S100B has been shown to contain acidic calcium and zinc binding domains that 
are thought to be involved in the interaction of S100B with tau (Baudier & Cole, 1988). 
The same study established that tubulin has “sequence homology with the acidic region 
of S100B subunits” (Baudier & Cole, 1988), from which they proposed that the acidic 
calcium-binding domains were involved in the interaction between S100B and tau. Tau 
proteins “consist of a half-N-terminal acidic portion followed by a proline-rich region and 
the C-terminal tail, which is the basic part of the protein” (Kolarova, Garcia-Sierra, 
Bartos, Ricny, & Ripova, 2012). There has been evidence to suggest that the “self-
aggregation of tau into filaments is inhibited by intact N- and C-termini” (Kolarova et al., 
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2012), and subsequently any abnormal phosphorylation or other alterations of either the 
N- or C- terminal “may induce a relaxed structural conformation in the tau molecule” 
which “allows the self-interaction between these sticky domains in the formation of 
PHFs” (Kolarova et al., 2012).  
The in vivo mechanism for how un-phosphorylated tau polymerizes into PHFs 
needs to be better understood so that therapeutic agents can be developed to target these 
pathological structures. Thus far, various investigators have established that it is possible 
to produce PHFs that are structurally equivalent to AD PHFs in vitro. However, a 
molecule has not been identified at elevated levels in vivo of AD-afflicted brains that 
induces tau polymerization at a rate comparable to the known in vitro inducers, heparin 
and arachidonic acid. Furthermore, cell culture studies have shown that various small 
molecules, including S100B, can enter various types of cells through the plasma 
membrane by an unknown mechanism, but this has not been shown in vivo. 
 A tau polymerization assay has been developed, using heparin as an inducer and 
other polyanions like S100B may also serve as inducers. The objective of this study was 
to determine the optimum ratio of S100B to tau, to see if S100B might logically be 
proposed as a physiological inducer of PHF formation.  In order to do this, an assay was 
employed that involved incubating purified tau protein at a range of concentrations with 
known inducer molecules heparin and arachidonic acid at varying concentrations (Shaun 
W. Carlson, 2007). Polymerization rate of tau was then measured as a function of the 
fluorescencegenerated by a thioflavin-S (ThS) dye molecule that binds only to the 
polymerized version of tau.  The same range of tau protein concentrations was then 
incubated under the same conditions with the inclusion of zinc-loaded S100B at a range 
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of concentrations.   S100B is a candidate for the currently unknown in vivo inducer of 
PHF formation, because it is up-regulated 20-fold in AD and because it has been 
established that zinc-loaded S100B can affect the activity of tau. The rate of 
polymerization of tau as a function of heparin, arachidonic acid or Zn(II)-S100B was 
measured with the Thioflavin-S fluorescence assay and the kinetics of the different 
inducers was compared.   
 Establishing S100B as a potential inducer molecule for PHF formation is one step 
toward identifying a potential therapeutic target for AD. 
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Chapter 2 
METHODS 
Tau Protein Expression and Purification 
Tau protein was first expressed in the Escherichia coli (E. coli) strain BL21, as 
described by (Barghorn, Biernat, & Mandelkow, 2005). The solution containing the 
bacteria was then centrifuged and the supernatant removed, resulting in a bacterial pellet. 
The bacterial pellet was then resuspended in cold resuspension buffer (20 mM MES, 1 
mM EGTA, 0.2 mM MgCl2, 5 mM dithiothreitol (DTT), 1 mM 
phenylmethylsulfonylfluoride (PMSF), 10 ug/mL leupeptin, 2 mM benzamidin, 10 
ug/mL pepstatin A, pH 6.8). The cells were disrupted by 3 rounds of sonication for 30 
seconds each round. Then, NaCl was added to a final concentration of 500 mM and the 
mixture was boiled for 20 minutes. The denatured proteins and cell debris were pelleted 
at 20,000g for 40 minutes at 4°C, and the supernatant was put into dialysis tubings (3.5 
kDa molecular weight cut-off) and dialyzed overnight in cation exchange 
chromatography buffer A, which consisted of the following: 20 mM MES, 50 mM NaCl, 
1 mM EGTA, 1 mM MgCl2, 2 mM DTT (freshly added), and 0.1 mM PMSF (freshly 
added), pH 6.8. The dialysate was centrifuged at 20,000g for 40 minutes at 4°C, and the 
clear supernatant was applied to a cation-exchange chromatography column. Unspecific 
proteins were washed out with cation exchange chromatography buffer A until the UV-
absorption reached a stable value. The tau protein was then eluted with a linear gradient 
of 60% final concentration of cation exchange chromatography buffer B, which consisted 
of 20 mM MES, 1 M NaCl, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT (freshly added), 0.1 
mM PMSF (freshly added), pH 6.8 and fractionated. Samples thought to contain tau had 
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aliquots removed and analyzed by SDS-PAGE. To do this, samples were mixed with 
SDS-sample buffer and separated on a 15% SDS-PAGE gel and then stained with 
Coomassie blue. In addition to the samples, a control tau protein from a previous 
preparation was run for comparison. Samples containing tau were then pooled and 
concentrated by ultrafiltration. The protein concentration of the final product was 
determined by spectrophotometry; a dilution of the samples was made and its absorption 
measured at 280 nm. Then, the extinction coefficient of 7,700 cm -1 M -1 was used to 
calculate the concentration of each sample. (Barghorn et al., 2005).   
S100B Purification 
 S100B expressed in E. coli was first grown in 1L of LB media at 37 °C with 
vigorous shaking. When A600 reached 0.7, 1mM IPTG was added and growth was 
continued for 3-4 hours. The cells were then harvested by centrifugation, washed one 
time with 50 mM Tris-HCl, pH 8.00, 5 mM MgCl2, and stored frozen at -80 °C. Cells 
were resuspended in a volume of 50 mM Tris-HCl, pH 8.00, 5 mM MgCl2 equal to 10 
times their packed weight, and then disrupted by 3 rounds of sonication for 30 seconds 
per round. Cell debris was removed by centrifugation for 15 minutes at 10,000 rpm. The 
supernatant solution was then centrifuged for 2 hours at 38,000 rpm. The supernatant 
solution was collected and ammonium sulfate was added, with stirring, to bring it to 90% 
of saturation. After the supernatant was collected, it was redissolved in 25 mM Tris-HCl, 
pH 8.0, 1 mM EDTA, and 1 mM DTT, and dialyzed overnight against the same buffer. 
 The dialyzed sample was applied to an anion exchange chromatography column. 
The column was equilibrated in 100% (v/v) buffer A, which consisted of 25 mM Tris-
HCl, pH 8.00, 1 mM EDTA, and 1 mM DTT, and elution was monitored at 280 nm with 
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a flow rate of 1 mL/min. After 30 minutes, the buffer was changed to 100% (v/v) buffer 
B, which consisted of 25 mM Tris-HCl, pH 8.00, 1 mM EDTA, 1 mM DTT, and 1 M 
NaCl. Samples thought to contain S100B had aliquots removed and analyzed by SDS-
PAGE. To do this, samples were mixed with SDS-sample buffer and separated on a 15% 
SDS-PAGE gel and then stained with Coomassie Blue. In addition to the samples, a 
control S100B protein from a previous preparation was run for comparison. Samples 
containing S100B were then pooled and concentrated by ultrafiltration. The protein 
concentration of the final product was determined by spectrophotometry; a dilution of the 
samples was made and its absorption measured at 280 nm. Then, the extinction 
coefficient of 1520 cm -1 M -1 was used to calculate the concentration of each sample. 
(Smith, et al, 1996) 
PHF Formation Assay 
Purified, full-length tau protein (tau40) ranging from 0 to 5 µM was incubated 
with heparin, at a final concentration of 5 µM and 0.1-10 µM  apo-S100B  and 0.1-10 µM  
Zn(II)-S100B. All samples also included 20 µM Thioflavin S, a dye molecule that binds 
only to the polymerized version of tau and thus provided the varying fluorescence by 
which the experiment was measured. Fluorescence measurements were taken at 440 nm 
excitation and 510 nm emission at 25 °C. Between readings, the samples were stored at 4 
°C.  
Tubulin Polymerization Assay 
8 µM >99% pure porcine tubulin (Cytoskeleteon, Inc.) and 1 mM GTP were 
incubated with either 0.8 µM tau, 0.476 µM Zn(II)-S100B, 0.476 µM Zn(II)-S100B + 0.8 
µM tau or 0.8 µM tau + 0.476 µM Zn(II), as a potential catalyst,  at room temperature and 
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the rate of tubulin polymerization was measured  by the change in absorbance at 350 nm 
over time. (Ennulat, Liem, Hashim, & Shelanski, 1989) and (Lee, et al.) 
Cell Culture 
A sample of SH-SY5Y cells was obtained as a generous gift from Dr. Michael 
Sierks, Arizona State University (ASU), and these cells were cultured in T-75 flasks 
containing a 1:1 mixture of Modified Eagle’s Medium and Ham’s F-12 (Irvine 
Scientific), supplemented with 10% Fetal Bovine Serum (Irvine Scientific), 1% 
antibiotic-antimycotic (Irvine Scientific), and 1% amino acids for MEM (Irvine 
Scientific). Cells were grown at 37 °C and 5% CO2, and passaged at 70-80% confluence.  
 After incubating with the experimental media for 24 or 72 hours, cells were plated 
on glass coverslips coated with a solution made from 2 mL sterile water, 200 µL collagen 
(400 µg/mL stock solution), 40 µL Poly D-Lysine (1 mg/mL stock solution) in 24-well 
plates at a density of 0.05 x 106 in 1 mL of complete media. 24 hours later, all trans-
retinoic acid was added to each well to a final concentration of 10 µM. Differentiation 
continued for 5 days, at which point the media was removed, and complete media was 
added back to each well. The experimental conditions were then added to each well, as 
seen in Table 1. After 24 or 72 hours, the cells were fixed in 2% paraformaldehyde for 15 
minutes, followed by permeabilization in 2% paraformaldehyde and 1% Tween20 in 
Intracellular Buffer (ICB, which consisted of 200 mM Hepes, 50 mM EGTA, 50 mM 
MgCl2 and 100 mM KCl) for 15 minutes. Cells were washed in 1X ICB for ten minutes, 
three times. Primary antibody (Santa Cruz Biotechnology, S-100 # chain (N-15)) was 
diluted 1:200 as recommended by the manufacturer and 200 µL were added to each well. 
The cells were incubated overnight at 4 °C on a rotary shaker, followed by another three 
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washes of ten minutes each in 1X ICB. Secondary antibody (Santa Cruz Biotechnology, d 
anti-goat IgG-FITC) was diluted 1:500 as recommended by the manufacturer and 200 uL 
of this solution were added to each well. The cells were incubated again overnight at 4 °C 
on a rotary shaker, followed by another three washes of ten minutes each in 1x ICB. The 
coverslips were then removed from the wells, mounted on microscope slides, sealed with 
clear nail polish and allowed to dry before being imaged. 
 
Table 1. Samples for cell culture and S100B imaging. All samples were plated at the 
same density (0.05 x 106 cells/well) and had experimental conditions and culture media 
added to a final volume of 1 mL 
 
SH-SY5Y Cell Imaging 
SH-SY5Y cells were plated at a density of 0.05 x 106 cells/well in a 24 well plate 
and incubated with a range of concentrations (0.5-5 µM) of apo-S100B and Zn(II)-loaded 
S100B as well as controls of 0.5-5 µM S100B + EDTA. All experimental conditions and 
culture media were added to a final volume of 1 mL. After 24 or 72 hours, each sample 
was fixed and attached to a microscope slide and imaged on a Nikon Video Microscope 
after 24 or 72 hours of incubation (Table 1).  
Firing Rate Analysis 
Hippocampal neurons were seeded at a density of 60,000/mm2 on two separate 
microelectrode arrays (MEA), produced and provided by Dr. Jitendran Mathuswamy, 
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ASU, and the cells were grown for 5-6 days (Khraiche and Muthuswamy, 2012). Both 
samples had 0.5 µM S100B added to the media, and their neuronal activity was 
monitored for 10 minutes to obtain a baseline level of activity monitored via the number 
of spikes per second by a multichannel recording system. Then, 0.5 µM EDTA was added 
to one sample and 0.75 µM Zn(II) was added to the other and the samples were incubated 
for 36 hours at 37 °C and 5% CO2. S100B has a dissociation constant for Zn(II) ranging 
from 10-8 – 10-6 M, which is rather high and indicates a very tight binding interaction 
between the two (Baudier & Gerard, 1983). Thus, it can be assumed that the Zn(II) did in 
fact bind to the S100B prior to the recording of activity at 36 hours post incubation. The 
activity of the neurons on the microelectrodes was then monitored for another ten 
minutes after the 36 hours of incubation with the use of the same multichannel recording 
system. Each MEA had 16 recording electrodes, and each electrode’s data was recorded 
separately. 
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Chapter 3 
RESULTS 
PHF Assay 
 The PHF assay showed an increase of ThS fluorescence from days 1-4 post-
incubation, and a drop in fluorescence between days four and five for the samples 
containing 50 µM tau incubated with 10 µM ThS and and 0.476 µM Zn(II)-S100B or 50 
µM tau incubated with 10 µM ThS and 5 µM heparin. The sample with S100B showed a 
higher level of fluorescence overall, suggesting that the tau assembled into PHFs at a 
faster rate in the presence of the Zn(II)-S100B than it did in the presence of heparin 
alone. Samples containing 50 µM tau incubated with 10 µM ThS showed little change in 
absorbance over the five day period (Figure 5). 
 
Figure 5. PHF Formation Assay 50 µM tau40 incubated with 10 µM ThS and: no 
heparin or S100B (crosses), 5 µM heparin (open circles) or 0.476 µM Zn(II)-S100B 
(closed circles). 
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Tubulin Polymerization Assay 
 In the tubulin polymerization assay, absorbance (measured at 350 nm) of samples 
containing 8 µM tubulin incubated with 1 mM GTP and 0.8 µM tau, 8µM tubulin 
incubated with 1 mM GTP and 0.476 µM Zn(II)-S100B,  8 µM tubulin incubated with 1 
mM GTP and 0.476 µM Zn(II)-S100B and 0.8 µM tau and 8 µM tubulin incubated with 1 
mM GTP and 0.8 µM tau and 0.476 µM Zn(II) increased over time from 0-1500 seconds. 
Sample A had a rate of 4.29 nM/sec, which was a much faster rate of PHF formation than 
samples B (1.39 nM/sec), C (1.27 nM/sec), and D (0.467 nM/sec). Samples B and C were 
similar in rate and sample D significantly slower. A fifth sample, E, containing only 8 
µM tubulin and 1 mM GTP showed negligible change in absorbance over time (Figure 
6). 
 
Figure 6. Tubulin polymerization assay. 8 µM tubulin was incubated with 1 mM GTP 
and with: 0.8 µM tau40 (A), 0.476 µM Zn(II)-S100B (B), 0.476 µM Zn(II)-S100B + 0.8 
µM tau40 (C), 0.8 µM tau40 + 0.476 µM Zn(II) (D), and without anything else added (E). 
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SH-SY5Y Cell Imaging 
 SH-SY5Y neuroblastoma cells were cultured in the presence of 0.5 or 5.0 µM 
S100B + EDTA or 0.5 or 5.0 µM Zn(II)-S100B for 24 or 72 hours. Samples incubated 
with 0.5 µM Zn(II)-S100B showed slight increases in the length of neuritic extensions 
compared to control cells (without anything added), and samples incubated with 5.0 µM 
Zn(II)-S100B showed approximately 30% more cell death compared to other samples 
(Figure 7).  
 
Figure 7. SH-SY5Y Cell Imaging. SH-SY5Y neuroblastoma cell images after 24 and 72 
hours. 
Firing Rate Analysis 
 The sample that contained S100B + Zn(II) showed increased firing rate in 15 of 
the 16 channels present on the MEA, with a greater than 50% increase in firing rate in 14 
of those channels. The sample that contained S100B + EDTA showed an increase in 
firing rate in 9 of 16 channels, with a greater than 50% increase in firing rate in 6 of those 
channels. (Figure 8.)  
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Figure 8. Firing Rate Analysis Activity of neurons after the addition of apo-S100B 
(blue) and EDTA-S100B (red top) or Zn(II)-S100B (red bottom). 
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Chapter 4 
DISCUSSION 
The results of the performed experiments suggest several possible avenues for 
continued research on the role of S100B in Alzheimer’s related processes.  
 
PHF Formation Assay 
In the PHF formation assay, samples that contained 50 µM tau incubated with 10 
µM ThS and 0.476 µM Zn(II)-S100B or 50 µM tau incubated with 10 µM ThS and 5 µM 
heparin showed an increase of ThS fluorescence from days 1-4 post-incubation, and a 
drop in fluorescence between days four and five. The sample that contained S100B 
showed a higher level of fluorescence overall, suggesting that the tau assembled into 
PHFs at a faster rate in the presence of the Zn(II)-S100B than it did in the presence of 
heparin alone. Samples containing 50 µM tau incubated with 10 µM ThS showed little 
change in absorbance over the five day period (Figure 4). Based on what is already 
known about S100B, it is likely that it has some effect on tau which affects tau’s ability 
to associate with microtubules, thus creating excess soluble tau that eventually forms 
PHFs and subsequently NFTs. As discussed previously, S100B contains acidic binding 
domains that may bind to the basic domain of tau. It has also been reported that “S100B 
interacts in a Ca(II) and Zn(II) dependent manner with purified tau protein” (Baudier & 
Cole, 1988). A particular cysteine residue, Cys84, which is located in the acidic c-terminal 
region of S100B and has been implicated in being important in S100B binding target 
proteins has been shown to be exposed to solvent when S100B is bound to Ca(II) (Landar 
et al., 1997) . When S100B is bound to Zn(II), the same residue is protected due to the 
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conformation of S100B (Baudier & Cole, 1988). This suggests that metal bound S100B 
has varying conformations that may affect its binding capabilities. What remains 
unknown, however, is the mechanism by which all of this occurs. If the mechanism of 
S100B binding tau could be ascertained, a novel therapeutic target could be developed 
more easily. 
 
Tubulin Polymerization Assay 
The tubulin polymerization assay was designed to further ascertain what effects 
Zn(II)-S100B may have on microtubules. The sample containing 8 µM tubulin incubated 
with 1 mM GTP and 0.8 µM tau showed the fastest rate of polymerization at 4.29 
nM/sec, while samples containing 8 µM tubulin and 0.476 µM Zn(II)-S100B or 8 µM  
and 0.476 µM Zn(II)-S100B + 0.8 µM tau40 showed a slower, but similar rate of 
polymerization (1.39 nM/sec and 1.27 nM/sec respectively) and the sample containing 8 
µM tubulin and 0.8 µM tau40 + 0.476 µM Zn(II) showed a further decreased rate of 
polymerization (0.467 nM/sec). The control sample, which contained only 8 µM tubulin 
and 1 mM GTP showed no polymerization. These results suggest that the addition of 
Zn(II)-S100B slows down the rate at which tubulin can polymerize into microtubules. 
What was of interest was that the sample that contained tubulin and Zn(II)-S100B, but no 
tau, polymerized at a similar rate to the sample that contained tubulin, Zn(II)-S100B and 
tau. It may have been expected that the sample containing tau would have a faster 
polymerization rate than the sample without tau, based on tau’s normal functionality as it 
relates to tubulin polymerization and the stability of resulting microtubules. Instead, these 
results suggest that the tau that was present may have been affected by the Zn(II)-S100B 
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that was also present and was subsequently unable to perform its normal functions. 
However, as discussed regarding the PHF formation assay, the mechanism for how 
S100B affects tau still remains unknown. These results provide evidence that Zn(II)-
S100B affects tau, but we do not know precisely how. It was previously discussed that 
studies have shown evidence of Ca(II)-S100B inhibiting tubulin polymerization, which 
underscores the significance of the metal-bound state of S100B toward its physiological 
function. Zn(II)-S100B, on the other hand, appears to be stimulating tubulin 
polymerization and these data suggest that tau may be competing with Zn(II)-S100B for 
the same binding site on tubulin. If this is the case, then the presence of Zn(II)-S100B in 
AD could be of critical importance. It has already been discussed that it appears to be 
metal bound S100B that is physiologically significant, and these data support that notion. 
It is known that zinc levels in the brain are elevated in AD (Bjorklund et al, 2012), which 
could shift the equilibrium levels of S100B to more of its zinc-bound state in AD. While 
the activity of Zn(II)-S100B catalyzed tubulin polyermization is lower than the activity 
catalyzed by tau, there is so much more Zn(II)-S100B present in AD, which could 
explain the increase in neuritic extensions observed in the SH-SY5Y cells incubated with 
similar concentrations of Zn(II)-S100B.  It is also known that the conformations of 
Ca(II)-S100B and Zn(II)-S100B are different, and thus may have different affinities for 
or capabilities of binding to various target proteins. If Zn(II)-S100B binds to tubulin in a 
similar manner to tau and thus the two compete, it could have important implications for 
designing a therapeutic target that affects neurofibrillary tangles. 
 
SH-SY5Y Imaging 
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In an effort to characterize the effect of S100B on the morphology of neuronal 
cells, SH-SY5Y cells were cultured in the presence of 0.5 or 5.0 µM tau or 0.5 or 5.0 µM 
Zn(II)-S100B + tau for 72 hours; samples incubated with tau alone showed little change 
in morphology over the time period. Samples incubated with 0.5 µM Zn(II)-S100B and 
tau showed slight increases in the length of neuritic extensions compared to wild type 
cells, and samples incubated with 5.0 µM Zn(II)-S100B and tau showed excessive cell 
death (Figure 7). This suggests that there may be a difference in the effect of Zn(II)-
S100B and tau on cell morphology based on concentration. In AD, Zn(II)-S100B is found 
at a concentration of 5 µM, which is the concentration at which excessive cell death was 
seen as well as the concentration that showed no tubulin polymerization in the 
aforementioned tubulin polymerization assay. The excessive cell death seen in these 
results corresponds to the neurodegeneration that is also found in AD, and cell death 
could relate to disturbances in the equilibrium status of microtubules. If the microtubules 
are not stable enough to continually support the typical structure of a neuron, it stands to 
reason that the cells would eventually collapse and die. An exact cause for the 
neurodegeneration seen in AD has yet to be ascertained, and these results suggest a 
possible avenue for future research in the area. 
 
Firing Rate Analysis 
Finally, in the firing rate analysis, evidence is provided that suggests that Zn(II)-
S100B affects the activity of neurons. This is particularly interesting; the firing rate of the 
neurons was increased when incubated with Zn(II)-S100B for 36 hours, but not when 
incubated with S100B+EDTA. This suggests that the S100B must be zinc loaded (or 
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perhaps otherwise loaded with a similar metal) in order to affect the firing rate. Affecting 
neural firing rate is another possible avenue for therapeutic treatments, and further 
experiments to characterize the effect that difference concentrations of Zn(II)-S100B may 
have on the firing rate of neurons would be useful. It has been shown previously that 
neurites in patients with AD exhibit delays in their firing rate when they have elevated 
levels of Aβ plaques (Knowles et al., 1999). It would follow that PHFs and NFTs may 
cause similar delays in neuron firing rate, but this idea has not yet been studied. 
 
Summary 
Results of the experiments reported, herein, support the theory that S100B plays a 
role in AD. Future research would certainly be warranted in establishing a more concrete 
relationship between the S100B and tau proteins, particularly what effect S100B has on 
the phosphorylation of tau and how Zn(II)-S100B stimulates PHF formation without 
inducing tau phosphorylation. It would also be valuable to determine how Zn(II)-S100B 
catalyzes tubulin polymerization at the biochemical and cellular levels.  This information, 
coupled with an elucidation of how Zn(II)-S100B influences neuronal activity, could help 
narrow the focus on how this protein could be targeted for AD therapeutic development.
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